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Abstract. Endometrial cancer is the most common female
reproductive cancer in the United States and is associated with
deregulated tight junction protein expression. Given the highly
estrogen-responsive nature of this tissue, we investigated the
effects of estrogen and its agonist, 4-OH TAM, on the expression and subcellular localization of the tight junction protein
claudin-4 (CLDN-4), in HEC-1A endometrial cancer cells. In
untreated HEC-1A cells, we observed dramatic overexpression of claudin-4 protein. In addition, differential detergent
extraction analysis indicated that claudin-4 was localized
primarily in the membrane but also found in the cytosolic,
nuclear and cytoskeletal fractions. Upon exposure of HEC-1A
to estradiol (E2), we observed a biphasic effect both on the
overall expression of claudin-4 protein and on its cytosolic and
cytoskeletal presence as demonstrated by immunoblot analysis.
Immunofluorescence analysis also revealed a biphasic effect
of E2 on claudin-4 expression. In contrast, we observed no
changes in expression levels nor in the subcellular distribution
patterns of claudin-4 in HEC-1A cells treated with different
concentrations of 4-OH TAM. The intracellular presence of
CLDN-4 coupled with the biphasic effects of E2 on CLDN-4
expression in the cytoskeleton suggest that this protein may be
involved in cell signaling to and from TJs.
Introduction
According to the American Cancer Society (1), endometrial
cancer is the most common female reproductive cancer in the
United States with an incidence of 1 in 37 women. The effects
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of estradiol (E2) on reproductive tract structure and function are
well known. Recently, however, studies have indicated a role
for E2 in tumor initiation and progression through its promotion of the proliferative, migratory and invasive capabilities of
cells (2-6). Many of the changes that occur in the endometrium
during tumorigenesis are similar to those observed during
implantation. For example, both processes exhibit diminished
endometrial cell to cell attachment through destabilization of
tight junctions (TJs), expression of matrix metalloproteinases,
differential expression of integrins and angiogenesis (7).
TJs consist of a complex of proteins located on the apical
side of cells and are important for regulating paracellular
transport and maintaining cell polarity (8). Furthermore, TJs
are essential for the tight sealing of cellular sheets necessary to
preserve the structural integrity of tissues and organs. Recent
studies also suggest a role for TJ proteins in recruiting signaling
proteins that regulate processes such as gene transcription,
cellular proliferation, differentiation and morphogenesis (8).
The TJ protein complex consists of three types of integral
membrane proteins; claudins (CLDNs), occludin and junctional
adhesion molecules (JAMs). Claudins are the predominant
molecular component of TJs and are essential both for their
assembly and function (8,9). CLDNs belong to a 24-member
protein family that display distinctive tissue-specific expression and are involved in multiple normal cellular processes. In
addition, alterations in CLDN gene expression or changes in
subcellular localization have been shown to be associated with
tumor progression (10).
Specifically, increases in CLDN-3 and -4 expression have
been observed in uterine serous papillary carcinoma (11,12),
clear-cell endometrial carcinoma (11) and uterine carcinosarcoma (13). Notably, overexpression of CLDN-3 and -4 was
associated with a poor clinical outcome (12). Endometrioid
adenocarcinomas expressing particularly high levels of
claudin-3 and -4 proteins have been found by electron
microscopy to exhibit morphologically disrupted TJs (10).
Consistent with these findings, overexpression of these two
claudin proteins has been positively correlated with tumor
progression in the endometrium and increased myometrial
invasion (10). In contrast to the overexpression of claudin-3
and -4 observed in endometrial cancer, endometriosis appears

cuevas et al: Claudin-4 expression in endometrial cancer cells

to be associated with a decrease in the levels of these two
proteins (13,14).
The reason for the upregulation of claudin-3 and -4 in
certain endometrial tumors is currently unclear but given its
role in the physiology of the endometrium, it is possible that E2
may be involved. Whereas two previous studies have shown that
exposure of MCF-7 breast cancer cells to low concentrations
of E2 results in a decrease in claudin-4 gene expression (15,16),
there are very few published studies demonstrating the effects
of E2 on claudin expression in endometrial cancer cells. In the
current study, therefore, we investigated the effects of varying
E2 concentrations on the expression and subcellular localization of CLDN-4.
Materials and methods
Cell lines and tissue culture conditions. The endometrial
cancer call line HEC-1A was obtained from ATCC (Manasas,
VA, USA) and cultured in McCoys 5A supplemented with 10%
fetal bovine serum (FBS) and 1% penicillin/streptomycin/2 mm
L-glutamine (PSG) purchased from Life Technologies. Cells
were maintained at 37˚C in a 5% CO2 atmosphere.
Compounds. The compounds estradiol (E2) and 4-hydroxytamoxifen (4-OH TAM) were purchased from Sigma and
dissolved in 100% ethanol, stored, and protected from light in
stock solutions of 1 mM at -20˚C. The final concentration of
ethanol in culture media was always <0.1% (v/v).
E 2 and 4-OH tamoxifen exposure experiment. Cells were
plated (2x10 5 cells/well) into 6-well plates or seeded
(1x106 cells) onto 25 cm 2 culture flask and cultured with their
respective media supplemented with 10%FBS-1% PSG for
48 h. Logarithmic phase cells were washed twice with PBS
and cells were serum starved for 24 h before the medium
was replaced with 10% charcoal treated fetal bovine serum
(CSFBS) (HyClone) with different concentrations of E 2
or 4-OH TAM ranging from 0-100 nM. The medium was
replaced daily to ensure constant hormone concentration.
Cells were harvested after 48 h to prepare whole cells protein
extracts or subcellular fractions.
Subcellular fractionation. HEC-1A cells were treated with
a series of commercial extraction buffers (Calbiochem)
according to manufactures instructions to obtain cytosolic,
membranous, nuclear and cytoskeletal fractions.
Western blot analysis. Proteins in whole cell extracts and
subcellular fractions were suspended in 4X sample buffer
(40% v/v glycerol, 4% SDS, 0.5% w/v bromophenol blue,
10% β-mercaptoethanol and 0.16 M Tris, pH 7.0), subjected
to electrophoresis on precast 12% SDS-polyacrylamide gels
and electrophoretically transferred to Immobilon-P PVDF.
The membranes were probed for 1 h at room temperature with
2 µg/ml rabbit polyclonal claudin-3, 3 µg/ml mouse monoclonal
claudin-4 (Life Technologies) or 1 µg/ml of rabbit anti-actin
(I-19) (Santa Cruz Biotechnology, Santa Cruz, CA, USA)
primary antibodies in 5% milk/PBS solution. Subsequently,
the membranes were incubated with 1:3000 horseradish
peroxidase-conjugated secondary antibody (goat anti-rabbit or
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goat-anti mouse; IgG; Bio-Rad Laboratories) for 1 h at room
temperature. For signal detection the enhanced chemiluminescence ECL-plus kit (Amersham, Buckinghamshire, UK) was
used according to manufacturer's instructions.
Confocal microscopy. Untreated or hormone treated log phase
cells were harvested and plated at 5x105 cells per chambered
coverslide (Lab-Tek, Fisher Scientific) and grown at 37˚C until
80% confluency. Cells were then rinsed with pre-cooled PBS
three times and fixed in pre-cooled 95% ethanol for 30 min
on ice. Following rehydration in PBS slides were blocked with
3% BSA, 0.05% saponin in PBS. Claudin-4 anti-sera (1:250)
(Life Technologies) was applied overnight at 4˚C, followed by
three wash cycles with PBS-saponin and incubation with goat
anti-mouse-IgG conjugated to Rhodamine Red-X (Jackson
ImmunoResearch) for 1 h at room temperature. Nuclei were
counterstained with Hoechst 33342 (1:1000) and filamentous
actin stained with Alexa 647-Phalloidin (1:500) followed
by PBS washing and treatment with Prolong Gold antiFade
Reagent (Life Technologies). High-resolution 1024X1024
images were collected using a Nikon A1R confocal system
with the 40X Plan Fluor NA 1.4 oil objective. The images
were thresholded, normalized and maximum intensity projections from 8 µm z-stacks were collected. Fluorescent image
intensity was quantified and presented as the mean ± SEM.
Significantly different groups were determined by ANOVA
with Tukey's HSD analysis (p<0.05).
Results
Claudin-4 expression in normal human tissues and reproductive cancer cell lines. To determine the variation of
expression of CLDN-4 in normal tissues, we analyzed a
panel of protein extracts derived from human bladder, breast,
cervix, kidney, ovary, placenta, prostate, testis and uterus
(pre-made tissue western blot purchased from ProSci). As
seen in Fig. 1 the strongest expression of CLDN-4 was seen
in the placenta, followed by the bladder, cervix and kidney. A
very faint signal was observed in prostate and breast tissue.
There was no obvious expression of CLDN-4 in the uterus,
ovary and testis.
In contrast to the low expression of CLDN-4 in normal
uterine tissue (Fig. 1), the endometrial adenocarcinoma cell
line HEC-1A, showed robust expression of CLDN-3 and -4
(Fig. 2). A less intense CLDN-4 signal was observed in the
endometrial cancer cell line RL95-2. There was no detectable signal in the cancer cell lines HEC-1B (endometrial),
HeLa (cervical) and SK-OV-3 (ovarian). Similarly, there
were non-detectable to low levels of CLDN-3 in all but the
HEC-1A cancer cells. These data indicate that the CLDN-3
and CLDN-4 proteins are abnormally overexpressed in the
HEC-1A cell line (Fig. 2). In summary, these data show
differential expression patterns of CLDN-3 and -4 between
the different cancer cell lines.
Subcellular localization of claudin-4 protein. We used
differential detergent cell fractionation, to assess the subcellular localization of CLDN-4 in HEC-1A cells. As shown in
Fig. 3, we observed CLDN-4 expression in all four subcellular
fractions, cytosolic (C), membranous (M), nuclear (N) and
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Figure 1. Claudin-4 (CLDN-4) expression in a panel of normal human tissues. A pre-made western blot (ProSci) containing a panel of protein extracts derived
from different human tissues was probed with anti-claudin-4. The strongest expression of CLDN-4 was seen in the placenta, followed by bladder, cervix and
kidney, A very faint signal was observed in prostate and breast. There was no detectable expression of CLDN-4 in the uterus, ovary and testis.

Figure 2. Overexpression of claudin (CLDN)-3 and -4 in the endometrial
cancer cell line HEC-1A. A panel of female reproductive cancer cell lines
was subjected to immunoblot analysis using antibodies to claudin-3, -4 and
actin. Overexpression of CLDN-3 and -4 was observed in the endometrial
adenocarcinoma cell line HEC-1A relative to cervical (HeLa), ovarian
(SK‑OV-3) and the endometrial (RL95-2 and HEC-1B) cancer cell lines.

Figure 3. Subcellular localization of claudin-4 (CLDN-4) in HEC-1A cells
by differential detergent fractionation. Immunoblots containing subcellular
fractions of HEC-1A cells were probed with anti-CLDN-4. The majority of
CLDN-4 was localized in the membrane fraction (M) and cytoskeletal (Csk)
fractions with readily detectable signal in both the nuclear (N) and cytosolic
(C) fractions. The blot is representative of 3 separate experiments.

cytoskeletal (Csk). The most intense signals were in the
membranous and cytoskeletal fractions.
Effects of E2 on CLDN-4 expression and subcellular localization. Cells were serum-starved for 24 h then exposed to
10-100 nM E2/CSFBS for 48 h. The medium was replaced daily
to ensure constant hormone concentration. As a control, one
set of cells was grown in FBS-containing medium. Whole cell
protein extracts (Fig. 4A) and subcellular fractions (Fig. 4B)
were subsequently analyzed for CLDN-4 expression by immunoblot analysis. As shown in Fig. 4A, E2 effected CLDN-4

Figure 4. Biphasic effect of estradiol on claudin-4 (CLDN-4) expression in
HEC-1A cells. Cells were exposed to a range of estradiol concentrations
(0-100 nM) in CSFBS for 72 h. As a control, one set of cells was grown
in media containing FBS. Whole cell protein extracts (A) and four cellular
subfractions (B) cytosolic (C), membranous (M), nuclear (N), and cytoskeletal (Csk) were subsequently analyzed for CLDN-4 (~22 kDa) expression
by immunoblot analyis. Actin was used as a loading control. Estradiol
increased CLDN-4 expression with a biphasic effect seen at the two highest
concentrations. We observed alterations in the pattern of CLDN-4 subcellular distribution in response to different estradiol concentrations. The blot is
representative of 3 separate experiments.

expression in a biphasic manner with the most intense signal
observed at 50 nM E2. In addition, we observed alterations in
the pattern of CLDN-4 subcellular distribution in response
to different E2 concentrations. Regardless of the E2 concentration, CLDN-4 expression was predominantly observed in
the membrane fraction (Fig. 4B). We observed evidence of a
biphasic E2 effect on both the cytosolic and cytoskeletal presence of CLDN-4 in HEC-1A cells. Specifically, there was a
high level of CLDN-4 in cells treated with 0, 10 and 100 nm
E2 with barely detectable levels in cells treated with 50 nM
E2. Furthermore, high levels of CLDN-4 were observed in the
cytoskeletal fractions of cells treated with 10 nM but not in
those cells treated with 0 nM and 50 nM E2.
Effects of 4-OH tamoxifen on CLDN-4 expression and
subcellular localization. We evaluated the expression of
CLDN-4 in response to various 4-OH TAM concentrations
(0-100 nM) and found it to be concentration-independent
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Discussion

Figure 5. Induction of claudin-4 (CLDN-4) expression by 4-OH tamoxifen
(4-OH TAM) in HEC-1A cells. Cells were exposed to a range of 4-OH TAM
concentrations (0-100 nM) in CSFBS for 72 h. As a control, one set of cells
was grown in media containing FBS. Whole cell protein extracts (A) and
four cellular subfractions (B) cytosolic (C), membranous (M), nuclear (N)
and cytoskeletal (Csk) were subsequently analyzed for CLDN-4 (~22 kDa)
expression on immunoblots. Actin was used as a loading control. Non-dose
dependent induction of claudin-4 expression by 4-OH TAM was observed.
However, the effect was not biphasic in nature. No dramatic alterations in
the pattern of CLDN-4 subcellular distribution were observed in response
to different 4-OH TAM concentrations with the exception of a modest dosedependent increase in signal in the nuclear fraction. Blot is representative of
3 separate experiments.

(Fig. 5A). Similarly, the subcellular distribution pattern of
CLDN-4 was also 4-OH TAM-independent. Specifically, we
observed the most intense CLDN-4 signal in the membranous
fraction closely followed by the cytosolic fraction (Fig. 5B).
Readily detectable bands were also observed in the cytoskeletal fraction of the cells exposed to 10-100 nM 4-OH TAM.
However, only barely detectable levels of CLDN-4 were
observed in the nuclear fractions at all concentrations.
Effects of E2 on CLDN-4 expression and localization by
immunofluorescence. CLDN-4 localization was evaluated by
indirect immunofluorescence using laser scanning confocal
microscopy. E2 supplementation (Fig. 6A) enhanced CLDN-4
expression and localization at cell-cell contacts. HEC-1A
cells cultured in the absence of E2 expressed modest levels
of CLDN-4 with localization distributed between the cytoplasm and membrane. E2 (10 nM) resulted in a shift toward
membrane localization with a slight elevation in expression.
Robust elevation of CLDN-4 signal occurred with 50 nM E2
supplementation as indicated by clearly delineated cell-cell
contacts and a marked elevation in intensity. CLDN-4 signal
was apparent in HEC-1A cells treated with 100 nM E2 but the
junctional intensity was diminished and intracellular signal
more frequent. Quantitation of CLDN-4 fluorescent intensity
is presented in Fig. 6B with significant differences found
between each E2 treatment group. HEC-1A cells cultured in
defined media with FBS exhibited CLDN-4 specific staining
at the perijunctional actin ring (Fig. 6C). The junctional intensity of CLDN-4 from cells cultured in media with FBS was
statistically undistinguishable from cells cultured in 100 nM
E2 (Fig. 6B).

There is a growing body of evidence suggesting that alterations in CLDN expression may be involved in the progression
of some cancers (17) such as endometrial carcinoma (11).
However, the regulation of these changes in expression are
not well understood. Thus, the current study sought to investigate the potential role of E2 and the chemotherapeutic drug,
4-OH TAM, on CLDN-4 expression in the endometrial cancer
cell line HEC-1A.
Our findings show that whereas CLDN-4 is either not
expressed or barely expressed in the endometrial cell lines
HEC-1B and RL95-2, respectively, it is dramatically overexpressed in HEC-1A cancer cells. Furthermore, CLDN-3
was also overexpressed in HEC-1A relative to the other
two endometrial cancer cell lines. Notably, there was no
detectable CLDN-4 expression in the normal uterine tissue.
These findings are consistent with previous studies that have
demonstrated elevated CLDN-4 expression with increased
endometrial tumor grade (10-12). In addition, the observed lack
of CLDN-4 expression in normal uterine tissue agrees with
previous studies that demonstrated absent or weak CLDN-4
expression in normal endometrial cells (NEC), proliferative
and secretory endometrial tissue (10,11).
Currently, the regulation of CLDN-4 expression in endometrial cells is not well understood. Owing to its major role
in the endometrium, we investigated the possible effects
of E2 and 4-OH TAM, a known E 2 partial agonist in the
endometrium, on the expression of CLDN-4. Notably, we
observed a clear biphasic effect of E2 on CLDN-4 expression. The lowest levels of expression were seen at 10 nM
and 100 nM E2 whereas the level of CLDN-4 expression
increased following exposure to 50 nM E2 as demonstrated by
both immunoblot and immunofluorescent analyses. Similar
to our findings, Gadal et al (16) also observed a decrease in
CLDN-4 gene expression in MCF-7 breast cancer cells upon
exposure to 10 nM E2. In contrast, Someya et al (18) showed
a dose-dependent increase in CLDN-4 protein expression in
the Sawano uterine cancer cell line with the highest levels of
expression observed at 100 µM. It should be noted, however,
that the concentrations of E2 used in the latter study are above
the normal physiological range.
Whereas we and others have shown a biphasic effect of E2
in endometrial and breast cancer cells, Zeng et al (19) did not
observe an E2 biphasic effect on CLDN-4 expression in human
cervical cells. This discrepancy is likely attributable to inherent
differences between the two tissue types studied. In addition to
CLDN-4, E2 has been shown to have a biphasic effect on the
levels of another tight junction protein, occludin, in both human
vascular epithelial cells (20) and cervical cells (19).
As a complement to the above E2 exposure studies we
treated the HEC-1A cells with the endometrial estrogen
agonist, 4-OH TAM. Decreased CLDN-4 expression occurred
only at concentrations of 100 nM 4-OH TAM. Owing to the
differential effects of 4-OH TAM on endometrial and breast
tissues, it is not surprising that Gadal et al (16) observed an
increase in CLDN-4 gene expression following treatment of
MCF-7 breast cancer cells with 100 nM 4-OH TAM.
We next determined the effect of E2 on the subcellular
localization of CLDN-4 in HEC-1A cells. Using differential
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Figure 6. E2-induced intracellular redistribution of claudin-4 (CLDN-4) in HEC-1A cells. Cells were cultured onto chambered coverslides and treated with
0-100 nM E2. Representative maximum intensity projection images are presented in (A) following CLDN-4 indirect immunofluorescence. Fluorescent image
intensity was quantified and presented as the mean ± SEM (B). Letters indicate significantly different groups as determined by ANOVA with Tukey's HSD
analysis (p<0.05). (C) Representation of HEC-1A cells cultured in media with FBS. A composite image is presented in addition to the individual channels.
Junctional CLDN-4 corresponds to perijunctional F-actin localization. Nuclei were counterstained with Hoechst 33342 and filamentous actin was labeled with
Alexa 647 phallodin. Scale bar, 50 µm.

detergent extraction analysis, we observed CLDN-4 in all
four subcellular fractions, membranous, cytosolic, nuclear
and cytoskeletal. Specifically, high levels of CLDN-4 were
observed in the nuclear fraction at the highest E2 concentration (100 nM). This contrasts with the barely detectable
nuclear fraction-specific signal at all other concentrations
(0-50 nM). In addition, we observed a biphasic effect of E2 on
CLDN-4 expression in the cytoskeletal fraction of HEC-1A
cells. Immunofluorescence analysis also showed a biphasic

effect of E2 on the expression of claudin-4 with a shift to
an intracellular localization of claudin-4 with increasing E2
concentration.
Whereas the expression of CLDN-4 in the membrane is
expected as a part of its role in the TJ, the significance of the
intracellular localization is not clear. Previous studies have
reported delocalization of CLDN proteins. For example,
Zhu et al (20) observed the presence of CLDN-1, -3, and -4
in the cytoplasm of cells from ovarian epithelial tumors by
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immunofluorescence analysis. Furthermore, Leotlela et al (21)
found that CLDN-1 was expressed almost exclusively in the
nucleus of benign nevi, or birthmarks, whereas it was located
in the cytosolic and membranous fractions in highly metastastic melanoma cells. Lejeune et al (22) showed that the shift
of CLDN-4 from the membrane to the cytoskeleton upon
exposure of T84 human colonic cells to the host inflammatory mediator prostaglandin E2 correlates with dissociation of
CLDN-4 from the TJ and is possibly responsible for the rapid
changes in TER that they subsequently observed.
Phosphorylation of CLDN proteins also appears to play
a role in their subcellular localization. D'Souza et al (23)
demonstrated that the phosphorylation of CLDN-3 on a
threonine residue alters the localization of this protein within
the membrane and the cytoplasm of ovarian OVCA433
cancer cells. Similarly, phosphorylation of CLDN-4 in HT29
colorectal adenocarcinoma cells weakens the association
between CLDN-4 and ZO-1, leading to an increased presence
of CLDN-4 in the cytoplasm (24). Furthermore, research has
shown that phosphorylation of CLDN-1 in human melanoma
cells can result in the redistribution of CLDN-1 to the nucleus
or cytoplasm (25).
Our findings underscore the dynamic nature of the TJ
as evidenced by the changes in subcellular localization of
CLDN-4 upon exposure to E2. Just how these changes in
subcellular localization come about is unclear. However, it
has been shown that CLDNs can be removed from the plasma
membrane by endocytosis into cytoplasmic vesicles (26)
and they have been found in extracellular exosomes of
cancer tissues (27). However, endocytosis and exocytosis
do not explain how an integral membrane protein, with four
hydrophobic (27) domains, can dissolve in the cytosol and
translocate to the nucleus despite the absence of a nuclear
localization sequence (28). The delocalization of CLDNs may
indicate a role for CLDN proteins in cell signaling pathways
with the PDZ domain of CLDNs providing a promising site for
the formation of signaling complexes (29).
Due to their frequent overexpression in numerous cancers
and function as receptors for Clostridium perfringens
enterotoxin (CPE), CLDN-3 and -4 have been considered as
useful targets in treating tumors overexpressing one or both
proteins, such as uterine serous papillary carcinoma (30).
To prevent wide-spread cytolysis by use of this therapy,
researchers have focused on a non-cytotoxic C-terminal fragment of CPE to specifically bind CLDN-3 or -4, altering the
TJ, and subsequently allowing for better drug absorption by
affected cells (31). Furthermore, the changes in CLDN-3 and
-4 expression in certain cancers have suggested that these
proteins may be potential prognostic markers. Indeed, a recent
study developed a so-called CURIO score based on CLDN-4
and E-cadherin expression in breast cancer. This score has
proven generally accurate in predicting a poorer prognosis
for those patients whose breast tumors overexpress these two
proteins (32).
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